Express Script's Chief Drug Procurement Officer to Deliver Keynote at CBI's 7th Annual Bio/Pharma Trade and Channel Strategies E

BOSTON, Oct. 18, 2011 /PRNewswire/ -- Allen Dunehew, Chief Drug Procurement Officer, Express Scripts, will present the keynote address at CBI's 7th Annual Bio/Pharma Trade and Channel Strategies on December 6-7, 2011 in Philadelphia. Dunehew will discuss industry trends and the impact of the PBM at the "Evolution of the PBM/Manufacturing Channel Relationship and Innovations in Supply and Distribution of Brands, Generics and Specialty Rx" session.

Over the years, Trade and Channel Strategies has become the meeting to attend for more than 1,000 life science suppliers and allied healthcare trading partners who convene to discuss next-generation agreements, distribution services, and innovative channel programs.

This year's event features an in-conference Specialty/Retail Channel Strategy Summit that examines new approaches and patient-centered opportunities through the specialty and retail channel. Eighteen speakers round out the event with extended industry panel discussions and a Wall Street address. Networking opportunities are available both days with such industry leaders as Genzyme, Ortho-McNeil, Sunovion Pharmaceuticals, Millennium Laboratories, CVS Caremark, Eli Lilly, GlaxoSmithKline, Bristol Myers Squibb, Johnson & Johnson, Covidien, and more.

For more information about the conference visit http://www.cbinet.com/trade.  

Contact: Cathy Rossi-Cecere
Phone number: 339-298-2128
Email address: [email protected]

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE CBI

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.